Ani Pharmaceuticals Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Ani Pharmaceuticals Inc's ROA in the second quarter of 2026?
Ani Pharmaceuticals Inc achieved a return on average assets (ROA) of 7.38 % in its second quarter of 2026, this is above ANIP's average return on assets of -5.35%.
Ani Pharmaceuticals Inc assets over the 12 months ending in its second quarter of 2026 are valued at $1,444 million

Despite the company's net income deteriorating, Ani Pharmaceuticals Inc was able to improve its ROA compared to the first quarter of 2026.

However, within the Healthcare sector 124 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 950, from total ROA ranking in the first quarter of 2026 at 1250.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	11.25 %	10.02 %	4.04 %	9.38 %	45.86 %
Y / Y Net Income Change	169.04 %	88.07 %	-	-	-
Net Income (TTM) in million	107	92	78	41	-10
Return On Assets (TTM)	7.38 %	6.55 %	5.7 %	2.98 %	-0.77 %
ANIP's Total Ranking	# 950	# 1250	# 1580	# 2700	# 2819
Total Assets (TTM) in million	1,494	1,422	1,451	1,408	1,343
Seq. Total Assets Change	5.07 %	-2.03 %	3.07 %	4.85 %	3.91 %
Seq. Net Income Change	-22.01 %	7.28 %	3.28 %	211.35 %	-45.48 %

ANIP's 5 Years Annual ROA >> Back to ANIP Management Effectiveness >> Compare ANIP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 47
Sector	# 125
Overall	# 844

Return On Assets Statistics
High	Average	Low
22.05 %	-5.35 %	-91.83 %
(Dec 31 2014)		(Dec 31 2011)

News about Ani Pharmaceuticals Inc Return on Assets ROA

ANI Pharmaceuticals Launches Combined Promethazine and Dextromethorphan Oral Solution for Enhanced Respiratory Reli...

ANI Pharmaceuticals, Inc. has announced the successful launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, a novel therapeutic solution designed for symptom management in respiratory ailments. This formulation delivers effective antitussive and antihistaminic effects, presenting a significant advancement for healthcare providers and patients alike. Respiratory illnesses remain a pivotal challenge in clinical management and patient health, often requiring effective symptomatic treatment. Promethazine Hydrochloride and Dextromethorphan Hydrobromide are well-documented compounds known for their respective roles as an antihistamine and cough suppressant. The recent introduction of their combined oral solution by ANI Pharmaceuticals marks a strategic step towards offering an optimized therapeutic option for both pediatric and adult patients.

Financial Statements
Ani Pharmaceuticals Inc's Assets	$ 1,494 million	ANIP's Balance sheet
Ani Pharmaceuticals Inc's Income	$ 23 million	Quarterly ANIP's Income Statement
ANIP's Income by Division		See ANIP's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	12.21 %	41.94 %	18.99 %	-1.49 %	67.31 %
Total Assets in million	1,440	1,284	904	760	772
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	78	-19	19	-48	-43
Annual Return On Assets	5.44 %	-1.44 %	2.08 %	-6.3 %	-5.52 %

ANIP's 5 Years Annual ROA >> Back to ANIP Management Effectiveness >> Compare ANIP ROA to its Competitors

Comment on ANIP's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 5.44 % compared to prior year, due to annual net income growth of % to $78.34 million, while value of Ani Pharmaceuticals Inc's overall assets grew just by 12.21 % to $1,440.38 million, compared to $1,440.38 a year before.

More Return On Assets Ratios
ANIP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ANIP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ANIP's Competitors
Subscribers only: Roa for Ani Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Assets for ANIP's Customers

You may also want to know
ANIP's Roi	ANIP's Inventory Turnover Ratio	ANIP's Growth Rates	ANIP's Dividend Comparisons
	ANIP's Profitability Ratios	ANIP's Asset Turnover Ratio	ANIP's Dividend Growth
ANIP's Roe	ANIP's Valuation Ratios	ANIP's Financial Strength Ratios	ANIP's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %
Aveanna Healthcare Holdings Inc	13.82 %
West Pharmaceutical Services Inc	13.64 %
Medinotec Inc	13.38 %
Puma Biotechnology Inc	13.28 %
Sbc Medical Group Holdings Incorporated	13.26 %
Alpha Pro Tech Ltd	13.17 %
Illumina Inc	12.68 %
Spero Therapeutics Inc	12.57 %
Transmedics Group Inc	12.50 %

Date modified: 2026-09-08T15:22:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.